General
Preferred name
BAVISANT
Synonyms
Bavisant (dihydrochloride) ()
JNJ-31001074 ()
JNJ31001074AAC ()
JNJ31001074 (dihydrochloride hydrate) ()
Bavisant (dihydrochloride hydrate) ()
BAVISANT DIHYDROCHLORIDE ()
Bavisant dihydrochloride hydrate ()
Bavisant dihydrochloride monohydrate ()
Ben-2001 ()
JNJ-31001074-AAC ()
P&D ID
PD058151
CAS
929622-08-2
1103522-80-0
929622-09-3
Tags
available
drug candidate
Drug indication
Attention deficit hyperactivity disorder
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Bavisant is a highly selective, orally active antagonist of the human H3 receptor. It is a novel mechanism of action, involving wakefulness and cognition. It has potential to be used as a treatment for ADHD. It was developed by Johnson & Johnson and has completed a phase II ADHD trial, but there has been no progress.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
The dihydrochloride hydrate salt form of Bavisant which is an orally bioavaliable and selective H3 receptor antagonist that could probably useful in the treatment of Attention-deficit hyperactivity disorder(ADHD). It is known to have been completed the Ph
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Bavisant dihydrochloride is the dihydrochloride form of Bavisant, which is a highly selective, orally active antagonist of the human H3 receptor. It may be used as a treatment for ADHD. It was developed by Johnson & Johnson and has completed a phase II ADHD trial, but there has been no progress.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
329.21
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
1
cLogP
1.44
TPSA
36.02
Fraction CSP3
0.63
Chiral centers
0.0
Largest ring
6.0
QED
0.84
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Histamine Receptor
HRH3
Pathway
Immunology/Inflammation
GPCR/G protein
Neuronal Signaling
MOA
Histamine Receptor antagonist
Solubility
10 mM in DMSO
Source data